Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Patterson

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|January 17, 2020
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitorsJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology|November 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemiaShirong Liu, Amanda Kofides, Xia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
Blood|February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Nicholas Tsakmaklis, Guang Yang, et al.
Haematologica|November 12, 2009
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemiaZachary R Hunter, Robert J Manning, Christine Hanzis, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Blood Advances|January 16, 2026
Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom MacroglobulinemiaNickolas Tsakmaklis, Zachary R Hunter, Xia Liu, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|January 17, 2020
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitorsJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology|November 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemiaShirong Liu, Amanda Kofides, Xia Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180Steven P Treon, Leukothea Ioakimidis, Jacob D Soumerai, et al.
Blood|February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Nicholas Tsakmaklis, Guang Yang, et al.
Haematologica|November 12, 2009
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemiaZachary R Hunter, Robert J Manning, Christine Hanzis, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Blood Advances|January 16, 2026
Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom MacroglobulinemiaNickolas Tsakmaklis, Zachary R Hunter, Xia Liu, et al.
Pageof 11